| Molecular profiling of the residual disease of triple-negative breast cancers after neoadjuvant chemotherapy identifies actionable therapeutic targets JM Balko, JM Giltnane, K Wang, LJ Schwarz, CD Young, RS Cook, ... Cancer discovery 4 (2), 232-245, 2014 | 542 | 2014 |
| MYC and MCL1 cooperatively promote chemotherapy-resistant breast cancer stem cells via regulation of mitochondrial oxidative phosphorylation K Lee, JM Giltnane, JM Balko, LJ Schwarz, AL Guerrero-Zotano, ... Cell metabolism 26 (4), 633-647. e7, 2017 | 506 | 2017 |
| Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, A Servetto, AB Hanker, VM Jansen, JA Bauer, ... Nature communications 10 (1), 1373, 2019 | 306 | 2019 |
| Activation of MAPK pathways due to DUSP4 loss promotes cancer stem cell-like phenotypes in basal-like breast cancer JM Balko, LJ Schwarz, NE Bhola, R Kurupi, P Owens, TW Miller, H Gómez, ... Cancer research 73 (20), 6346-6358, 2013 | 159 | 2013 |
| Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence JM Balko, LJ Schwarz, N Luo, MV Estrada, JM Giltnane, ... Science translational medicine 8 (334), 334ra53-334ra53, 2016 | 139 | 2016 |
| Association of FGFR1 with ERα maintains ligand-independent ER transcription and mediates resistance to estrogen deprivation in ER+ breast cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 23 (20), 6138-6150, 2017 | 126 | 2017 |
| The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer JD Joseph, B Darimont, W Zhou, A Arrazate, A Young, E Ingalla, K Walter, ... Elife 5, e15828, 2016 | 124 | 2016 |
| LYN-activating mutations mediate antiestrogen resistance in estrogen receptor–positive breast cancer LJ Schwarz, EM Fox, JM Balko, JT Garrett, MG Kuba, MV Estrada, ... The Journal of clinical investigation 124 (12), 5490-5502, 2014 | 50 | 2014 |
| Extended Adjuvant Therapy with Neratinib Plus Fulvestrant Blocks ER/HER2 Crosstalk and Maintains Complete Responses of ER+/HER2+ Breast Cancers … DR Sudhan, LJ Schwarz, A Guerrero-Zotano, L Formisano, MJ Nixon, ... Clinical Cancer Research 25 (2), 771-783, 2019 | 40 | 2019 |
| An ERBB1-3 neutralizing antibody mixture with high activity against drug-resistant HER2+ breast cancers with ERBB ligand overexpression LJ Schwarz, KE Hutchinson, BN Rexer, MV Estrada, PI Gonzalez Ericsson, ... JNCI: Journal of the National Cancer Institute 109 (11), djx065, 2017 | 39 | 2017 |
| ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors AL Guerrero-Zotano, TP Stricker, L Formisano, KE Hutchinson, DG Stover, ... Clinical Cancer Research 24 (11), 2517-2529, 2018 | 32 | 2018 |
| Impact of the delayed initiation of adjuvant chemotherapy in the outcome of triple negative breast cancer Z Morante, R Ruiz, JM Araujo, JA Pinto, G de la Cruz-Ku, ... Clinical Breast Cancer 21 (3), 239-246. e4, 2021 | 29 | 2021 |
| Patterns of mutation enrichment in metastatic triple-negative breast cancer CH Saravia, C Flores, LJ Schwarz, L Bravo, J Zavaleta, J Araujo, ... Clinical Medicine Insights: Oncology 13, 1179554919868482, 2019 | 21 | 2019 |
| Helicobacter pylori: History and facts in Peru I Tirado-Hurtado, C Carlos, L Lancho, A Alfaro, R Ponce, LJ Schwarz, ... Critical Reviews in Oncology/Hematology 134, 22-30, 2019 | 13 | 2019 |
| Precision medicine for locally advanced breast cancer: frontiers and challenges in Latin America JA Pinto, CH Saravia, C Flores, JM Araujo, D Martínez, LJ Schwarz, ... ecancermedicalscience 13, 2019 | 11 | 2019 |
| Abstract GS6-05: Gain-of-function kinase library screen identifies FGFR1 amplification as a mechanism of resistance to antiestrogens and CDK4/6 inhibitors in ER+ breast cancer L Formisano, Y Lu, VM Jansen, JA Bauer, A Hanker, P Gonzalez Ericsson, ... Cancer Research 78 (4_Supplement), GS6-05-GS6-05, 2018 | 9 | 2018 |
| Influence of sex in the molecular characteristics and outcomes of malignant tumors JM Araujo, G Rosas, C Belmar-Lopez, LE Raez, CD Rolfo, LJ Schwarz, ... Frontiers in Oncology 11, 752918, 2021 | 8 | 2021 |
| Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer JD Joseph, B Darimont, W Zhou, A Arrazate, A Young, E Ingalla, K Walter, ... Elife 8, e44851, 2019 | 4 | 2019 |
| Correction: Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer L Formisano, KM Stauffer, CD Young, NE Bhola, AL Guerrero-Zotano, ... Clinical Cancer Research 25 (4), 1433-1433, 2019 | 2 | 2019 |
| Abstract S6-01: JAK2 amplifications are enriched in triple negative breast cancers (TNBCs) after neoadjuvant chemotherapy and predict poor prognosis JM Balko, JM Giltnane, LJ Schwarz, ME Sanders, K Wang, LN Harris, ... Cancer Research 73 (24_Supplement), S6-01-S6-01, 2013 | 2 | 2013 |
